CONTENTS
Issue 94 | May 2020
In association with
A brief history of mumps and mumps treatments in the UK
What happens to virus whistleblowers after they blow the whistle?
Peptomyc and the quest to develop a 'universal' cancer treatment
Is pharma ready to tackle the health effects of continued climate change?
Inactive pharmaceutical ingredients can make problems worse for patients
After the year of the mega-merger, will 2020 be the year of the pharma spin out?
Improving cancer treatment with precise, personalised targets
An inside look at the Signals Analytics drug development playbook
Turning attention towards patient benefits with IDMP data standards implementation